home / stock / ipha / ipha articles
The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause ...
News, Short Squeeze, Breakout and More Instantly...
Innate Pharma S.A. Company Name:
IPHA Stock Symbol:
NYSE Market:
The event will highlight positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome which have been selected for oral presentation at the American Society of Hematology (ASH) Annual Meeting Virtual K...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Innate Pharma S.A. (IPHA) is expected to report for Q3 2023